Robert Wessman

Chief Executive Officer

Professional Overview
Robert Wessman is a seasoned executive and entrepreneur with over two decades of experience in the pharmaceutical and biotechnology industries. As the Chief Executive Officer and Founder of Alvotech, he leverages his deep industry expertise to drive innovation and growth in the global biosimilars market.

Experience Summary

Current Role
As the CEO of Alvotech, Mr. Wessman is responsible for setting the strategic direction and overseeing the day-to-day operations of the company. Under his leadership, Alvotech has emerged as a leading global biopharmaceutical company, focused on developing high-quality biosimilar products that improve patient access to essential medicines. He has played a pivotal role in Alvotech's rapid expansion, guiding the company's successful entry into multiple international markets.

Career Progression
Prior to founding Alvotech, Mr. Wessman served as the Founder and Chairman of Aztiq, a private equity firm specializing in investments in the healthcare and pharmaceutical sectors. He also founded Adalvo, a global pharmaceutical company, and has held the position of Chairman at Alvogen, a leading international pharmaceutical company, since 2009. Additionally, he serves as the Chairman of the Board at Lotus Pharmaceutical Co., Ltd., a prominent Taiwanese pharmaceutical company.

Academic Background
Mr. Wessman holds a degree in Business Administration from the University of Iceland, where he honed his entrepreneurial and leadership skills.

Areas of Expertise
Throughout his career, Mr. Wessman has developed a deep understanding of the pharmaceutical and biotechnology industries, with particular expertise in the development and commercialization of biosimilar products. He is recognized for his strategic vision, strong operational acumen, and ability to navigate complex regulatory environments.

Professional Impact
Under Mr. Wessman's guidance, Alvotech has emerged as a global leader in the biosimilars industry, with a robust pipeline of high-quality products and a presence in multiple international markets. His entrepreneurial spirit and commitment to innovation have been instrumental in driving the company's success and expanding patient access to essential biopharmaceutical therapies.

Conclusion
With his extensive industry experience, proven track record of success, and unwavering dedication to advancing the field of biosimilars, Robert Wessman is poised to continue leading Alvotech's growth and solidifying its position as a premier global biopharmaceutical company.